Ross Toohey named Managing Director in Chesterfield, Missouri

NEW YORK - Amzeal -- STS Capital Partners is pleased to announce the appointment of Ross Toohey as a Managing Director. A founder-turned-M&A strategist with a track record of building, scaling, and successfully exiting businesses, Ross brings over two decades of experience across entrepreneurship, corporate development, and strategic advisory. Having led his own company through a premium private equity exit and advised others on both buy- and sell-side transactions, Ross offers a uniquely holistic perspective that enhances STS's ability to deliver Extraordinary Exits™ for founder-led and mid-market companies.

Ross began his entrepreneurial journey as CEO of 2e Group, a privately-owned omnichannel pharma/biotech commercialization agency that he scaled into one of North America's largest independent firms. He spearheaded strategic acquisitions and market expansions, positioning the business as a dominant industry force and securing an elite roster of Fortune 100 clients.

More on Amzeal News

• purelyIV Expands Mobile IV Therapy to Jackson, MI and Launches PlaqueX® IV Therapy
• Leimert Juneteenth Community Celebration Set for Friday, June 19, in Leimert Park Village
• UK Financial Ltd Publishes Maya Preferred Public Proof Package and CoinMarketCap Supply Verification Evidence
• Section 1 Partners with The Winning Moments for Interactive Championship Medals
• Advancing High-Potential Nevada Critical Minerals Portfolio as Major Drill Program Nears Assay Results: Glenstar Minerals: Stock Symbol: GSTRF

In 2019, Ross led the successful sale of 2e Group to medical communications leader Fishawack Health (now Avalere Health). Post-acquisition, he was appointed Chief Commercial Officer, overseeing corporate business development and M&A. During his tenure, Ross pioneered the now-ubiquitous concept of fully integrated pharma commercialization, helping drive the company's growth to over $1.1 billion in enterprise value.

Following his success in corporate M&A, Ross founded EONOVA, an exit planning and advisory firm. Through EONOVA, he leverages his expertise in leadership, strategic growth, and both buy- and sell-side M&A to help business owners identify valuation gaps, plan successful exits, and accelerate enterprise value. He is a sought-after strategic growth consultant, particularly for businesses in healthtech, pharma/biotech, and professional services.

Ross is a Certified Exit Planning Advisor (CEPA) and serves as Mid-Americas U.S. Regional Board Chairman-Elect for the Young Presidents' Organization (YPO).

More on Amzeal News

• Parents Say the Exhausting Part Isn't the Activity Itself
• Pervaziv AI Strengthens Trusted Agentic Engineering with Cortex 4.7
• Allstream Energy Partners to Host 6th Executive Networking After 2026 Energy Projects Conference
• Why Blood Glucose Meters Remain an Essential Part of Diabetes Monitoring?
• CAPHRA: Australia and Thailand show nicotine prohibition fuels illicit markets

"Ross has sat in the founder's seat, scaled a business into a market leader, and achieved a premium exit. Now, as an STS Managing Director, he draws on that firsthand experience to help our clients do the same – maximizing value and creating extraordinary outcomes," said Sean Friday, CEO of STS Capital Partners.

About STS Capital Partners:

STS Capital Partners is a global sell-side M&A firm like no other. We are expert guides for private, founder, and entrepreneurial business owners on the journey to achieving an Extraordinary Exit™. Our extensive global relationships, world-class team, and proven deal process bring international strategic buyers and investors to the table who deliver maximum financial value. As a result, we help clients fulfill bigger ambitions in life and leave lasting legacies by inspiring charitable donations through our Success to Significance™ program with a goal of raising billions of dollars in new philanthropic and impact capital to support charities like Altruvest, Knowledge Impact Network, and DignityMoves.